Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III afamelanotide implant study in erythropoietic protoporphyria
NL-OMON35418Phase 3Active, not recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jan 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Severity of phototoxic reactions. Started Jan 2010; status: active, not recruiting.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NL-OMON35418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35418.